Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  19,266 results for ""Palivizumab""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).

  • Authors : Tuffy KM; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. Electronic address: .; Ahani B

Subjects: Palivizumab*/Palivizumab*/Palivizumab*/therapeutic use ; Palivizumab*/Palivizumab*/Palivizumab*/administration & dosage ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/prevention & control

  • Source: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126276. Date of Electronic Publication: 2024 Sep 05.Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Improvement in Palivizumab Administration Prior to Discharge for Hospitalized Infants with Hemodynamically Significant Congenital Heart Disease: A Quality Improvement Initiative.

  • Authors : Jones AL; Division of Cardiology, Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania Perelmen School of Medicine, 3401 Civic Center Blvd, Philadelphia, PA, 19104, USA. .; Campbell MJ

Subjects: Palivizumab*/Palivizumab*/Palivizumab*/administration & dosage ; Palivizumab*/Palivizumab*/Palivizumab*/therapeutic use ; Quality Improvement*

  • Source: Pediatric cardiology [Pediatr Cardiol] 2024 Oct; Vol. 45 (7), pp. 1415-1423. Date of Electronic Publication: 2023 May 05.Publisher: Springer Verlag Country of Publication: United States NLM ID: 8003849 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.

Subjects: Palivizumab*/Palivizumab*/Palivizumab*/administration & dosage ; Palivizumab*/Palivizumab*/Palivizumab*/therapeutic use ; Antibodies, Neutralizing*/Antibodies, Neutralizing*/Antibodies, Neutralizing*/blood

  • Source: Pediatrics [Pediatrics] 2024 Nov 01; Vol. 154 (5).Publisher: American Academy of Pediatrics Country of Publication: United States NLM ID: 0376422 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro.

  • Authors : Lekic E; Department of Neonatology, Institute for Children's Diseases, University Clinical Center of Montenegro, Podgorica, Montenegro, Serbia.; Dragas L

Subjects: Palivizumab*/Palivizumab*/Palivizumab*/therapeutic use ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/prevention & control ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/epidemiology

  • Source: The Turkish journal of pediatrics [Turk J Pediatr] 2024 May 23; Vol. 66 (2), pp. 161-170. Date of Electronic Publication: 2024 May 23.Publisher: Hacettepe Medical Center Country of Publication: Turkey NLM ID: 0417505 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Cost Savings Without Increased Risk of Respiratory Hospitalization for Preterm Children after the 2014 Palivizumab Policy Update.

  • Authors : Levin JC; Division of Newborn Medicine, Boston Children's Hospital, Boston, Massachusetts.; Division of Pulmonary Medicine, Boston Children's Hospital, Boston, Massachusetts.

Subjects: Palivizumab*/Palivizumab*/Palivizumab*/therapeutic use ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/prevention & control ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/epidemiology

  • Source: American journal of perinatology [Am J Perinatol] 2024 May; Vol. 41 (S 01), pp. e133-e141. Date of Electronic Publication: 2022 May 06.Publisher: Thieme-Stratton Country of Publication: United States NLM ID: 8405212 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.

Subjects: Palivizumab*/Palivizumab*/Palivizumab*/therapeutic use ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/prevention & control ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use

  • Source: American journal of perinatology [Am J Perinatol] 2024 May; Vol. 41 (S 01), pp. e1107-e1115. Date of Electronic Publication: 2022 Nov 30.Publisher: Thieme-Stratton Country of Publication: United States NLM ID: 8405212 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Impact of respiratory tract infections on spinal muscular atrophy with focus on respiratory syncytial virus infections: a single-centre cohort study.

  • Authors : Rüsch CT; Neuromuscular Centre Zurich and Department of Pediatric Neurology, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.; Swiss Epilepsy Centre, Klinik Lengg, Zurich, Switzerland.

Subjects: Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/complications ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/prevention & control ; Respiratory Tract Infections*/Respiratory Tract Infections*/Respiratory Tract Infections*/prevention & control

  • Source: Swiss medical weekly [Swiss Med Wkly] 2024 Oct 01; Vol. 154, pp. 3573. Date of Electronic Publication: 2024 Oct 01.Publisher: Trägerverein Swiss Medical Weekly SMW Country of Publication: Switzerland NLM ID: 100970884 Publication Model: Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Respiratory syncytial virus immunization patterns in Germany, 2015-2020.

  • Authors : Wick M; Evidence-based Medicine / Health Economics & Outcomes Research, Sanofi-Aventis Deutschland GmbH, Berlin, Germany.; Kliemt R

Subjects: Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/prevention & control ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/epidemiology ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/economics

  • Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2380110. Date of Electronic Publication: 2024 Aug 08.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections.

  • Authors : Ramirez KA; LeBonheur Children's Hospital, Memphis, TN, United States; Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, United States

Subjects: Palivizumab*/Palivizumab*/Palivizumab*/therapeutic use ; Respiratory Syncytial Virus, Human*/Respiratory Syncytial Virus, Human*/Respiratory Syncytial Virus, Human*/drug effects ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/drug therapy

  • Source: Virology [Virology] 2023 Sep; Vol. 586, pp. 115-121. Date of Electronic Publication: 2023 Jul 18.Publisher: Academic Press Country of Publication: United States NLM ID: 0110674 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.

  • Authors : Gebretekle GB; Centre for Immunization Programs, Public Health Agency of Canada, Ottawa, ON, Canada.; Yeung MW

Subjects: Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/prevention & control ; Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/Respiratory Syncytial Virus Infections*/economics ; Cost-Benefit Analysis*

  • Source: Vaccine [Vaccine] 2024 Aug 30; Vol. 42 (21), pp. 126164. Date of Electronic Publication: 2024 Jul 30.Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  19,266 results for ""Palivizumab""